Cyclophosphamide | CAS#50-18-0 |

MedKoo Cat#: 592993 | Name: Cyclophosphamide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cyclophosphamide is a precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active ALDOPHOSPHAMIDE. It has been used in the treatment of LYMPHOMA and LEUKEMIA

Chemical Structure

Cyclophosphamide

CAS#50-18-0

Theoretical Analysis

MedKoo Cat#: 592993

Name: Cyclophosphamide

CAS#: 50-18-0

Chemical Formula: C7H15Cl2N2O2P

Exact Mass: 260.0200

Molecular Weight: 261.08

Elemental Analysis: C, 32.20; H, 5.79; Cl, 27.16; N, 10.73; O, 12.26; P, 11.86

Price and Availability

Size	Price	Availability
200mg	USD 285.00	2 Weeks
500mg	USD 550.00	2 Weeks
1g	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

50-18-0 6055-19-2 (hydrate)

Synonym

Cyclophosphamide

IUPAC/Chemical Name

2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide

InChi Key

CMSMOCZEIVJLDB-UHFFFAOYSA-N

InChi Code

InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)

SMILES Code

ClCCN(CCCl)P1(OCCCN1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic activity, a immunosuppressant.

In vitro activity:

It is established that low-dose CY not only decreases cell number but leads to decreased functionality of T(REGs). CY treatment enhances apoptosis and decreases homeostatic proliferation of these cells. Expression of GITR and FoxP3, which are involved in the suppressive activity of T(REGs), is down-regulated after CY administration, though the level of expression varies depending on the time studied. Reference: Blood. 2005 Apr 1;105(7):2862-8. https://linkinghub.elsevier.com/retrieve/pii/S0006-4971(20)45685-X

In vivo activity:

Cyclophosphamide (CTX) is often used to create a "window" for more effective therapeutic tumor vaccination. According to a commonly applied protocol, 2 mg CTX was injected intraperitoneally to mice with small (2 to 3 mm diameter) or large (5 to 7 mm, and in one experiment 8 to 10 mm diameter) subcutaneously growing tumors from the SW1 clone of the K1735 melanoma, euthanized the mice 4 days later and studied the composition of lymphoid cells by flow cytometry in both spleens and tumors. Administration of CTX increased the percentage of CD3, CD4, and CD8 cells with the increase in tumors being significantly greater than in spleens, and it also increased the percentage of B cells in spleens and tumors. Furthermore, CTX dramatically increased the frequency of tumor-infiltrating CD4 and CD8 cells containing interferon gamma, of cells expressing NK1.1, and of cells expressing the dendritic cell markers CD11c, CD80, and CD86, with the greatest increases seen among tumor-infiltrating lymphoid cells (TIL) from mice with small tumors. Although CTX decreased the percentage of TIL that expressed CD4 or CD8 together with CD25 and FoxP3 and were therefore considered to be regulatory T cells, it increased the frequency of TIL that stained for Gr1/CD11b, a marker for myeloid-derived suppressor cells. It was concluded that the administration of CTX can favorably impact several cell populations that are involved in tumor rejection. However, since CTX has a limited effect on TIL from tumors larger than a few millimeter in diameter and in view of an increased percentage of myeloid-derived suppressor cells among TIL from mice given CTX there is a need for more effective ways to improve tumor vaccination. Reference: J Immunother. 2010 Jan;33(1):53-9. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19952956/

	Solvent	mg/mL	mM
Solubility
	DMSO	32.1	122.80
	Water	29.7	113.83

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 261.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005 Apr 1;105(7):2862-8. doi: 10.1182/blood-2004-06-2410. Epub 2004 Dec 9. PMID: 15591121. 2. Liu P, Jaffar J, Hellstrom I, Hellstrom KE. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother. 2010 Jan;33(1):53-9. doi: 10.1097/CJI.0b013e3181b56af4. PMID: 19952956; PMCID: PMC2811714.

In vitro protocol:

In vivo protocol:

1. Liu P, Jaffar J, Hellstrom I, Hellstrom KE. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother. 2010 Jan;33(1):53-9. doi: 10.1097/CJI.0b013e3181b56af4. PMID: 19952956; PMCID: PMC2811714.